196 related articles for article (PubMed ID: 30028037)
1. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.
Ohanian M; Garcia-Manero G; Levis M; Jabbour E; Daver N; Borthakur G; Kadia T; Pierce S; Burger J; Richie MA; Patel K; Andreeff M; Estrov Z; Cortes J; Kantarjian H; Ravandi F
Am J Hematol; 2018 Sep; 93(9):1136-1141. PubMed ID: 30028037
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
Ravandi F; Alattar ML; Grunwald MR; Rudek MA; Rajkhowa T; Richie MA; Pierce S; Daver N; Garcia-Manero G; Faderl S; Nazha A; Konopleva M; Borthakur G; Burger J; Kadia T; Dellasala S; Andreeff M; Cortes J; Kantarjian H; Levis M
Blood; 2013 Jun; 121(23):4655-62. PubMed ID: 23613521
[TBL] [Abstract][Full Text] [Related]
3. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory
Short NJ; Daver N; Dinardo CD; Kadia T; Nasr LF; Macaron W; Yilmaz M; Borthakur G; Montalban-Bravo G; Garcia-Manero G; Issa GC; Chien KS; Jabbour E; Nasnas C; Huang X; Qiao W; Matthews J; Stojanik CJ; Patel KP; Abramova R; Thankachan J; Konopleva M; Kantarjian H; Ravandi F
J Clin Oncol; 2024 May; 42(13):1499-1508. PubMed ID: 38277619
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
5. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
Sasaki K; Kantarjian HM; Kadia T; Patel K; Loghavi S; Garcia-Manero G; Jabbour EJ; DiNardo C; Pemmaraju N; Daver N; Dalle IA; Short N; Yilmaz M; Bose P; Naqvi K; Pierce S; Yalniz F; Cortes JE; Ravandi F
Cancer; 2019 Nov; 125(21):3755-3766. PubMed ID: 31310323
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
Rautenberg C; Nachtkamp K; Dienst A; Schmidt PV; Heyn C; Kondakci M; Germing U; Haas R; Kobbe G; Schroeder T
Eur J Haematol; 2017 Apr; 98(4):348-354. PubMed ID: 27893163
[TBL] [Abstract][Full Text] [Related]
8. [Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].
Gu B; Chen GH; Shen HJ; Ma X; Fu CC; Han Y; Tang XW; Miao M; Qiu HY; Sun AN; Wu DP
Zhonghua Nei Ke Za Zhi; 2016 Apr; 55(4):293-7. PubMed ID: 27030618
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Patients with
Weng GY; You WW; Liu HX; Cai Y; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1333-1339. PubMed ID: 37846681
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.
Borthakur G; Zeng Z; Cortes JE; Chen HC; Huang X; Konopleva M; Ravandi F; Kadia T; Patel KP; Daver N; Kelly MA; McQueen T; Wang RY; Kantarjian H; Andreeff M
Am J Hematol; 2020 Nov; 95(11):1296-1303. PubMed ID: 32697348
[TBL] [Abstract][Full Text] [Related]
11. Gilteritinib or Chemotherapy for Relapsed or Refractory
Perl AE; Martinelli G; Cortes JE; Neubauer A; Berman E; Paolini S; Montesinos P; Baer MR; Larson RA; Ustun C; Fabbiano F; Erba HP; Di Stasi A; Stuart R; Olin R; Kasner M; Ciceri F; Chou WC; Podoltsev N; Recher C; Yokoyama H; Hosono N; Yoon SS; Lee JH; Pardee T; Fathi AT; Liu C; Hasabou N; Liu X; Bahceci E; Levis MJ
N Engl J Med; 2019 Oct; 381(18):1728-1740. PubMed ID: 31665578
[TBL] [Abstract][Full Text] [Related]
12. [Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation].
Zhang Y; Xuan L; Fan Z; Huang F; Jiang Q; Xu N; Gao Y; Sun J; Liu Q
Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):292-6. PubMed ID: 27093991
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.
Battipaglia G; Massoud R; Ahmed SO; Legrand O; El Cheikh J; Youniss R; Aljurf M; Mohty M; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):506-508. PubMed ID: 31122828
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
Ravandi F; Cortes JE; Jones D; Faderl S; Garcia-Manero G; Konopleva MY; O'Brien S; Estrov Z; Borthakur G; Thomas D; Pierce SR; Brandt M; Byrd A; Bekele BN; Pratz K; Luthra R; Levis M; Andreeff M; Kantarjian HM
J Clin Oncol; 2010 Apr; 28(11):1856-62. PubMed ID: 20212254
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
[TBL] [Abstract][Full Text] [Related]
16. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.
Brunner AM; Li S; Fathi AT; Wadleigh M; Ho VT; Collier K; Connolly C; Ballen KK; Cutler CS; Dey BR; El-Jawahri A; Nikiforow S; McAfee SL; Koreth J; Deangelo DJ; Alyea EP; Antin JH; Spitzer TR; Stone RM; Soiffer RJ; Chen YB
Br J Haematol; 2016 Nov; 175(3):496-504. PubMed ID: 27434660
[TBL] [Abstract][Full Text] [Related]
17. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
Al-Kali A; Cortes J; Faderl S; Jones D; Abril C; Pierce S; Brandt M; Kantarjian H; Ravandi F
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):361-6. PubMed ID: 21816375
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
Antar A; Kharfan-Dabaja MA; Mahfouz R; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):298-302. PubMed ID: 25550214
[TBL] [Abstract][Full Text] [Related]
19. Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
Xuan L; Wang Y; Huang F; Jiang E; Deng L; Wu B; Fan Z; Liang X; Xu N; Ye J; Lin R; Yin C; Zhang Y; Sun J; Han M; Huang X; Liu Q
Cancer; 2018 May; 124(9):1954-1963. PubMed ID: 29509276
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With
Burchert A; Bug G; Fritz LV; Finke J; Stelljes M; Röllig C; Wollmer E; Wäsch R; Bornhäuser M; Berg T; Lang F; Ehninger G; Serve H; Zeiser R; Wagner EM; Kröger N; Wolschke C; Schleuning M; Götze KS; Schmid C; Crysandt M; Eßeling E; Wolf D; Wang Y; Böhm A; Thiede C; Haferlach T; Michel C; Bethge W; Wündisch T; Brandts C; Harnisch S; Wittenberg M; Hoeffkes HG; Rospleszcz S; Burchardt A; Neubauer A; Brugger M; Strauch K; Schade-Brittinger C; Metzelder SK
J Clin Oncol; 2020 Sep; 38(26):2993-3002. PubMed ID: 32673171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
